T. Rowe Price Associates
PRCT icon

T. Rowe Price Associates’s Procept Biorobotics PRCT Stock Holding History

T. Rowe Price Associates’s Portfolio PRCT Stock Details PRCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$15.2M Sell
605,958
-99,782
-14% -$2.81M ﹤0.01% 1118
2025
Q4 		$22.2M Sell
705,740
-169,441
-19% -$5.62M ﹤0.01% 1048
2025
Q3 		$31.2M Sell
875,181
-447,258
-34% -$20.4M ﹤0.01% 941
2025
Q2 		$76.2M Buy
1,322,439
+266,677
+25% +$15.1M 0.01% 627
2025
Q1 		$61.5M Buy
1,055,762
+341,906
+48% +$23.3M 0.01% 661
2024
Q4 		$57.5M Sell
713,856
-63,574
-8% -$5.43M 0.01% 716
2024
Q3 		$62.3M Sell
777,430
-391,872
-34% -$27.8M 0.01% 697
2024
Q2 		$71.4M Sell
1,169,302
-298,357
-20% -$17.7M 0.01% 615
2024
Q1 		$72.5M Sell
1,467,659
-38,000
-3% -$1.81M 0.01% 620
2023
Q4 		$63.1M Sell
1,505,659
-250,844
-14% -$8.54M 0.01% 636
2023
Q3 		$57.6M Buy
1,756,503
+225,163
+15% +$7.68M 0.01% 642
2023
Q2 		$54.1M Buy
1,531,340
+187,575
+14% +$6.2M 0.01% 682
2023
Q1 		$38.2M Buy
1,343,765
+175,148
+15% +$6.18M 0.01% 755
2022
Q4 		$48.5M Buy
1,168,617
+97,383
+9% +$4.18M 0.01% 668
2022
Q3 		$44.4M Sell
1,071,234
-2,832,769
-73% -$113M 0.01% 683
2022
Q2 		$128M Buy
3,904,003
+58,511
+2% +$2.13M 0.02% 592
2022
Q1 		$135M Buy
3,845,492
+2,442,421
+174% +$58.8M 0.01% 639
2021
Q4 		$34.1M Buy
1,403,071
+62,087
+5% +$2.3M ﹤0.01% 1133
2021
Q3 		$49.7M Buy
+1,340,984
New +$51.5M ﹤0.01% 1013

Other funds holding PRCT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
BNP Paribas Asset Management
BNP Paribas Asset Management Paris, France $86.1B AUM 29.11% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
CC
Chicago Capital Chicago, Illinois $3.71B AUM 19.51% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
Mackenzie Financial
Mackenzie Financial Toronto Ontario, Ontario, Canada $83.3B AUM 31.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates's PRCT Position: Q1 2026 in Review

T. Rowe Price Associates reduced its Procept Biorobotics (PRCT) stake by 14% in Q1 2026, selling an estimated $2.81M and leaving 605,958 shares worth $15.2M. The position accounts for ﹤0.01% of the portfolio, ranked #1118.

T. Rowe Price Associates first reported a position in PRCT in Q3 2021 and has held it in 19 quarters since. The position peaked at $135M in Q1 2022. 256 funds tracked by Wall St. Rank hold PRCT as of Q1 2026.

  • T. Rowe Price Associates held 605,958 shares of Procept Biorobotics worth $15.2M as of Q1 2026.
  • T. Rowe Price Associates sold 99,782 Procept Biorobotics shares in Q1 2026, an estimated $2.81M.
  • Procept Biorobotics made up ﹤0.01% of T. Rowe Price Associates's portfolio in Q1 2026, its #1118 holding.
  • T. Rowe Price Associates first reported a position in Procept Biorobotics in Q3 2021 and has held it in 19 quarters since.
  • T. Rowe Price Associates's Procept Biorobotics position peaked at $135M in Q1 2022.
  • 256 funds tracked by Wall St. Rank held Procept Biorobotics as of Q1 2026.

Based on T. Rowe Price Associates's 13F filing for Q1 2026, filed 15 May 2026.